. "3"^^ . . "2011-12-31+01:00"^^ . . "0"^^ . . . "4725"^^ . "PRODUCTION OF RECOMBINANT IMMUNOCYTOKINES FOR TUMOR IMMUNOTHERAPY"@en . . "2007-01-01+01:00"^^ . . "\u00DA\u010Dinn\u00E1 l\u00E9\u010Dba n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED pomoc\u00ED vhodn\u00E9 imunomodulace je jedn\u00EDm z hlavn\u00EDch c\u00EDl\u016F sou\u010Dasn\u00E9 imunologie. A\u010Dkoliv IL-2 a IL-12 jsou jedn\u011Bmi z nejnad\u011Bjn\u011Bj\u0161\u00EDch cytokin\u016F pro imunoterapii n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED, kter\u00E9 byly testov\u00E1ny v mnoha klinick\u00FDch studi\u00EDch a IL-2 byl dokonce ofici\u00E1ln\u011B schv\u00E1len FDA pro l\u00E9\u010Dbu vybran\u00FDch malignit, dosavadn\u00ED v\u00FDsledky nejsou p\u0159\u00EDli\u0161 uspokojiv\u00E9. Jedn\u00EDm z hlavn\u00EDch d\u016Fvod\u016F je vysok\u00E1 toxicita, kter\u00E1 byla opakovan\u011B sledov\u00E1na po l\u00E9\u010Db\u011B vysok\u00FDmi d\u00E1vkami t\u011Bchto cytokin\u016F; dal\u0161\u00EDmi d\u016Fvody jsou extr\u00E9mn\u011B kr\u00E1tk\u00FD elimina\u010Dn\u00ED polo\u010Das, farmakokinetika a biodostribuce. C\u00EDlem tohoto projektu je produkce a testov\u00E1n\u00ED imunocytokin\u016F na b\u00E1zi IL-2 a IL-12. Hlavn\u00EDm bodem projektu je tedy vyvinout terapeuticky \u00FA\u010Dinn\u00E9 imunocytokiny, kter\u00E9 by byly schopn\u00E9 \u0159\u00EDdit expanzi a v\u00FDvoj efektorov\u00FDch funkc\u00ED jak naivn\u00EDch, tak pam\u011B\u0165ov\u00FDch CD8+ bun\u011Bk a tak\u00E9 NK bun\u011Bk."@cs . "Immunocytokine; IL-2; IL-12; cancer immunotherapy; immunomodulation; CD8+ cells; NK cells"@en . "4725"^^ . "1"^^ . . . "PRODUKCE REKOMBINANTN\u00CDCH IMMUNOCYTOKIN\u016E PRO \u00DA\u010CINNOU IMUNOTERAPII N\u00C1DOR\u016E"@cs . "3"^^ . "Effective cancer theraphy through immunomodulation is one of the most important long-term goal of imunology. Although IL-2 and IL-12, one of the most promising cytokines for tumor immunotheraphy, have been extensively tested in many clinical trials and IL-2 has been already approved by FDA for the treatment of some tumors, the results so far are not satisfactory. One of the main reason is high toxicity observed after high-dose tretment with these cytokines. The other reasons are extremely short half-life and pharmacokinetics and biodostribution. The aim of this project is to produce and test IL-2- and IL-12-based immunocytokines. The main point of this proposal is to develop potent and therapeutically efficient immunocytokines which would be able to significantly promote expansion and development of effector functions of both naive and memory CD8+ cells as well as NK cells."@en . "0"^^ . .